公开(公告)号：US20090304691A1

公开(公告)日：2009-12-10

申请号：US12467170

申请日：2009-05-15

Applicant: Jasbir Seehra ,  John Knopf ,  Robert S. Pearsall ,  Asya Grinberg ,  Ravindra Kumar

Inventor： Jasbir Seehra ,  John Knopf ,  Robert S. Pearsall ,  Asya Grinberg ,  Ravindra Kumar

IPC: A61K39/395 ,  C07K16/18 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/16 ,  A61P35/00

CPC classification number: C07K16/22 ,  A61K9/0048 ,  A61K38/1709 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/47 ,  C07K14/71 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.

Abstract translation: 在某些方面，本公开涉及以下认识：包含活化素样激酶I（ALK1）多肽的细胞外结构域的配体结合部分的多肽可用于抑制体内血管发生，特别是在血管生成相关的哺乳动物中 疾病 在某些方面，本公开表明BMP9和/或BMP10的拮抗剂，ALK1的配体也可用于抑制体内血管发生。

公开(公告)号：US07612040B2

公开(公告)日：2009-11-03

申请号：US11479181

申请日：2006-06-30

Applicant: John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

Inventor： John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

IPC: A61K38/16 ,  A61K38/18 ,  A61K38/19 ,  C07K14/00 ,  C07K14/475 ,  C07K14/51

CPC classification number: C07K14/47 ,  A61K38/00 ,  C07K14/495

Abstract: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.

Abstract translation: 本公开涉及Lefty衍生物和Lef多肽作为某些配体如Nodal，GDF-8（Myostatin）和GDF-11功能的拮抗剂的用途。 这些衍生物可以与其它功能异源蛋白如IgG，特别是IgG的Fc部分融合。 根据该公开内容，Lefty多肽可用于治疗各种疾病，包括例如神经元疾病，肌肉和骨骼状况以及代谢紊乱。

公开(公告)号：US20090148427A1

公开(公告)日：2009-06-11

申请号：US12254940

申请日：2008-10-21

Applicant: Gray D. Shaw ,  Dianne S. Sako ,  Ravindra Kumar ,  Francis Sullivan ,  Tom McDonagh

Inventor： Gray D. Shaw ,  Dianne S. Sako ,  Ravindra Kumar ,  Francis Sullivan ,  Tom McDonagh

IPC: A61K38/43 ,  A61K38/16

CPC classification number: C07K14/705 ,  A61K38/1709 ,  C07K2319/00

Abstract: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.

Abstract translation: 本发明提供了用于治疗或预防血管相关疾病的组合物和方法。

公开(公告)号：US20090038211A1

公开(公告)日：2009-02-12

申请号：US12025528

申请日：2008-02-04

Applicant: Rakesh Sarin ,  Ravindra Kumar ,  Suresh Kumar Puri ,  Anurag Ateet Gupta ,  Ravinder Kumar Malhotra ,  Satish Makhija

Inventor： Rakesh Sarin ,  Ravindra Kumar ,  Suresh Kumar Puri ,  Anurag Ateet Gupta ,  Ravinder Kumar Malhotra ,  Satish Makhija

IPC: C10L1/18

CPC classification number: C07C29/34 ,  C07C51/16 ,  C07C67/08 ,  C07C69/24 ,  C10L1/026 ,  C10L1/19 ,  C10L10/08 ,  C10L10/12 ,  C10L10/14 ,  Y02E50/13 ,  Y02T50/678 ,  C07C31/125 ,  C07C53/128

Abstract: Disclosed is a novel synthetic fuel as alternative to diesel, wherein said synthetic fuel comprises branched esters and wherein the fuel having improved fuel properties such as zero aromatic, zero olefin, zero sulphur, low pour, high cetane diesel fuel with improved lubricity and oxidative stability. Further, the present invention provides a method of preparation of said esters.

Abstract translation: 公开了一种新型合成燃料作为柴油的替代物，其中所述合成燃料包括支链酯，并且其中燃料具有改进的燃料性质，例如零芳香族，零烯烃，零硫，低倾倒，具有改善的润滑性和氧化稳定性的高十六烷值柴油 。 此外，本发明提供了所述酯的制备方法。

公开(公告)号：US20060094890A1

公开(公告)日：2006-05-04

申请号：US11077162

申请日：2005-03-11

Applicant: Meeta Sharma ,  Ravindra Kumar ,  Sinha Ray ,  Rakesh Sarin ,  Ravinder Malhotra ,  Ram Verma ,  Niranjan Raghunath

Inventor： Meeta Sharma ,  Ravindra Kumar ,  Sinha Ray ,  Rakesh Sarin ,  Ravinder Malhotra ,  Ram Verma ,  Niranjan Raghunath

IPC: C07C51/43

CPC classification number: C11C3/003 ,  Y02E50/13

Abstract: Disclosed herein is a single pot process for producing biodiesel and the product thereof, using non-edible oil sources containing free fatty acid. The process comprises esterification and transesterification of non-edible vegetable oil sources containing free fatty acids in a single pot employing a water scavenger or a water adsorbent or a mixture thereof.

Abstract translation: 本文公开了使用含有游离脂肪酸的非食用油源的用于生产生物柴油及其产物的单锅法。 该方法包括使用除水剂或水吸附剂或其混合物在单个罐中含有游离脂肪酸的非食用植物油源的酯化和酯交换。

公开(公告)号：US5843707A

公开(公告)日：1998-12-01

申请号：US428734

申请日：1995-04-25

Applicant: Glenn R. Larsen ,  Dianne S. Sako ,  Xiao-Jia Chang ,  Geertruida M. Veldman ,  Dale Cumming ,  Ravindra Kumar ,  Gray Shaw

Inventor： Glenn R. Larsen ,  Dianne S. Sako ,  Xiao-Jia Chang ,  Geertruida M. Veldman ,  Dale Cumming ,  Ravindra Kumar ,  Gray Shaw

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C07K19/00 ,  C12N9/10 ,  C12N9/64 ,  C12N15/12 ,  C12N15/85

CPC classification number: C12N9/6454 ,  C07K14/4703 ,  C07K14/705 ,  C07K16/2851 ,  C07K16/2854 ,  C07K19/00 ,  C12N9/10 ,  C12N9/1051 ,  A61K38/00 ,  A61K39/00 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/24 ,  Y10S514/844 ,  Y10S514/937 ,  Y10S514/944

Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.

Abstract translation: 公开了一种新型P-选择素配体糖蛋白，其包含SEQ ID NO：2所示的氨基酸序列或SEQ ID NO：4所示的氨基酸序列。 还公开了编码P-选择素配体蛋白的DNA序列，以及载体，宿主细胞和制备P-选择蛋白配体蛋白的方法。 还公开了含有P-选择素配体蛋白质的药物组合物和治疗由P-选择蛋白和E-选择素介导的细胞间粘附特征的炎性疾病状态的方法。

公开(公告)号：US5840679A

公开(公告)日：1998-11-24

申请号：US472576

申请日：1995-06-07

Applicant: Glenn R. Larsen ,  Dianne S. Sako ,  Xiao-Jia Chang ,  Geertruida M. Veldman ,  Dale Cumming ,  Ravindra Kumar ,  Gray Shaw ,  Ray Camphausen

Inventor： Glenn R. Larsen ,  Dianne S. Sako ,  Xiao-Jia Chang ,  Geertruida M. Veldman ,  Dale Cumming ,  Ravindra Kumar ,  Gray Shaw ,  Ray Camphausen

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C07K19/00 ,  C12N9/10 ,  C12N9/64 ,  C12N15/12 ,  A61K38/16 ,  A61K39/395 ,  C07K16/00 ,  G01N33/53

CPC classification number: C12N9/6454 ,  C07K14/4703 ,  C07K14/705 ,  C07K16/2851 ,  C07K16/2854 ,  C07K19/00 ,  C12N9/10 ,  C12N9/1051 ,  A61K38/00 ,  A61K39/00 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/24 ,  Y10S514/844 ,  Y10S514/937 ,  Y10S514/944

Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.

Abstract translation: 公开了一种新型P-选择素配体糖蛋白，其包含SEQ ID NO：2所示的氨基酸序列或SEQ ID NO：4所示的氨基酸序列。 还公开了编码P-选择素配体蛋白的DNA序列，以及载体，宿主细胞和制备P-选择蛋白配体蛋白的方法。 还公开了含有P-选择素配体蛋白质的药物组合物和治疗由P-选择蛋白和E-选择素介导的细胞间粘附特征的炎性疾病状态的方法。

公开(公告)号：US5827817A

公开(公告)日：1998-10-27

申请号：US477254

申请日：1995-06-07

Applicant: Glenn R. Larsen ,  Dianne S. Sako ,  Xiao-Jia Chang ,  Geertruida M. Veldman ,  Dale Cumming ,  Ravindra Kumar ,  Gray Shaw ,  Ray Camphausen

Inventor： Glenn R. Larsen ,  Dianne S. Sako ,  Xiao-Jia Chang ,  Geertruida M. Veldman ,  Dale Cumming ,  Ravindra Kumar ,  Gray Shaw ,  Ray Camphausen

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C07K19/00 ,  C12N9/10 ,  C12N9/64 ,  C12N15/12 ,  A61K38/17 ,  C07K7/08 ,  C07K14/435

CPC classification number: C12N9/6454 ,  C07K14/4703 ,  C07K14/705 ,  C07K16/2851 ,  C07K16/2854 ,  C07K19/00 ,  C12N9/10 ,  C12N9/1051 ,  A61K38/00 ,  A61K39/00 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/24 ,  Y10S514/844 ,  Y10S514/937 ,  Y10S514/944

Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.

公开(公告)号：US09932386B2

公开(公告)日：2018-04-03

申请号：US14112620

申请日：2012-04-19

Applicant: Asya Grinberg ,  Roselyne Castonguay ,  Eric Werner ,  Ravindra Kumar

Inventor： Asya Grinberg ,  Roselyne Castonguay ,  Eric Werner ,  Ravindra Kumar

IPC: C07K14/705 ,  A61K38/00

CPC classification number: C07K14/70596 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/23 ,  C07K2319/24 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/41 ,  C07K2319/50 ,  C07K2319/705

Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.

公开(公告)号：US08765663B2

公开(公告)日：2014-07-01

申请号：US13404593

申请日：2012-02-24

Applicant: Jasbir Seehra ,  Ravindra Kumar ,  Jennifer Lachey ,  Alan Koncarevic

Inventor： Jasbir Seehra ,  Ravindra Kumar ,  Jennifer Lachey ,  Alan Koncarevic

IPC: A61K38/00 ,  A61K39/00 ,  A61K39/395

CPC classification number: C07K16/40 ,  A61K31/00 ,  A61K31/7088 ,  A61K38/179 ,  A61K2039/505 ,  C07K14/705 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30

Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.

Abstract translation: 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。